Hanna N - Search Results

1

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.

Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N. Anderson DR, et al. Among authors: hanna n. Biochem Soc Trans. 1997 May;25(2):705-8. doi: 10.1042/bst0250705. Biochem Soc Trans. 1997. PMID: 9191187 Review. No abstract available.

2

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Reff ME, et al. Among authors: hanna n. Blood. 1994 Jan 15;83(2):435-45. Blood. 1994. PMID: 7506951 Free article.

3

Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.

Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Chinn PC, et al. Among authors: hanna n. Int J Oncol. 1999 Nov;15(5):1017-25. doi: 10.3892/ijo.15.5.1017. Int J Oncol. 1999. PMID: 10536187

4

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4.

Anderson D, Chambers K, Hanna N, Leonard J, Reff M, Newman R, Baldoni J, Dunleavy D, Reddy M, Sweet R, Truneh A. Anderson D, et al. Among authors: hanna n. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84. doi: 10.1006/clin.1997.4363. Clin Immunol Immunopathol. 1997. PMID: 9191886

5

"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4.

Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, Raab R, Reff M, Shuey S, Hanna N. Newman R, et al. Among authors: hanna n. Biotechnology (N Y). 1992 Nov;10(11):1455-60. doi: 10.1038/nbt1192-1455. Biotechnology (N Y). 1992. PMID: 1369023

6

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.

Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A. Newman R, et al. Among authors: hanna n. Clin Immunol. 2001 Feb;98(2):164-74. doi: 10.1006/clim.2000.4975. Clin Immunol. 2001. PMID: 11161972

7

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, Reff M, Newman R, Hanna N, Sweet RW, Truneh A. Reddy MP, et al. Among authors: hanna n. J Immunol. 2000 Feb 15;164(4):1925-33. doi: 10.4049/jimmunol.164.4.1925. J Immunol. 2000. PMID: 10657642

8

Antibody therapy of non-Hodgkin's B-cell lymphoma.

Chinn P, Braslawsky G, White C, Hanna N. Chinn P, et al. Among authors: hanna n. Cancer Immunol Immunother. 2003 May;52(5):257-80. doi: 10.1007/s00262-002-0347-6. Epub 2003 Feb 28. Cancer Immunol Immunother. 2003. PMID: 12700943 Review.

9

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.

Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Demidem A, et al. Among authors: hanna n. Cancer Biother Radiopharm. 1997 Jun;12(3):177-86. doi: 10.1089/cbr.1997.12.177. Cancer Biother Radiopharm. 1997. PMID: 10851464

10

Future approaches for treating hematologic disease.

Reff M, Braslawsky G, Hanna N. Reff M, et al. Among authors: hanna n. Curr Pharm Biotechnol. 2001 Dec;2(4):369-82. doi: 10.2174/1389201013378626. Curr Pharm Biotechnol. 2001. PMID: 11762418 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

768 results

Search Page